

1642

#6

SK 7/5/00

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


CERTIFICATE OF MAILING

I hereby certify that this SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Thomas E. Northrup
Thomas E. Northrup, Reg. No. 33,268

6-23-2000
Date

Applicant	:	Sherman)	
Serial No.	:	09/277,064)	Group: 1642
Filed	:	March 26, 1999)	Examiner: Unassigned
For	:	IN VIVO ACTIVATION OF TUMOR-SPECIFIC CYTOTOXIC T CELLS)	Our Ref. TSRI 433.1 D1



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

JUN 30 2000

Dear Sir:

TECH CENTER 1600/2900

In recognition of its continuing duty to disclose pursuant to 37 CFR §1.56, Applicant hereby submits the present Information Disclosure Statement in compliance therewith.

Pursuant to 37 CFR § 1.98(d), enclosed herewith are copies of the Information Disclosure Statement and Supplemental Information Disclosure Statement and accompanying PTO Forms 1449 filed in parent application 08/355,558 filed on December 14, 1994, now abandoned. Also, pursuant to 37 CFR §1.98(d), copies of the above references are not submitted herewith, as they are available in the parent patent application 08/355,558.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed

Serial No.: 09/277,064

TSRI 433.1 D1

references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR 1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(b) insofar as this statement is being filed within three months of the filing of the application/before the mailing date of a first Office Action.

Also, in accordance with 37 CFR 1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR 1.56 exists.

Respectfully submitted,

Dated: 6-23-2000

By Thomas E. Northrup
Thomas E. Northrup, Reg. No. 33,268

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.

April C. Logan
April C. Logan, Reg. No. 33,950

8 March 1995
Date

Applicant	:	Sherman)	
Serial No.	:	08/355,558)	Group Art Unit: Unknown
Filed	:	12/14/94)	
For	:	IN VIVO ACTIVATION OF TUMOR-SPECIFIC CYTOTOXIC T CELLS)	Examiner: Unassigned
)	Our Ref. TSRI 433.0



INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner
of Patents and Trademarks
Washington, D.C. 20231

RECEIVED

JUN 30 2000

TECH CENTER 1600-2000

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR 1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith. Copies of the references cited therein are also enclosed, as explained further below.

The following references were cited in the application and are believed relevant for the reasons set forth in the specification: Di Fiore, et al., Science 237: 178 (1987); Dittmer, et al., Nature Gen. 4: 42 (1993); Falk, et al., Nature 351: 290 (1991); Harlow, et al., Mol. Cell. Biol. 5: 1601 (1985); Hinds, et al., Cell Growth Diff. 1: 571 (1990); Houbiers, et al., Eur. J. Immunol. 23: 2072-2077 (1993); Hunt, et al., Science 255: 1261 (1992); Ioannides, et

al., Cellular Immunol. 151: 225-234 (1993); Ioannides, et al., J. Immunol. 146: 1700 (1991); Irwin, et al., J. Exp. Med. 170: 1091 (1989); Melief and Kast, Curr. Op. Immunol. 5: 709-713 (1993); Vitiello, et al., J. Exp. Med. 173: 1007-1015 (1991); Winter, et al., Cancer Res. 52: 4168-74 (1992); Yoshino, et al., J. Immunol. 152: 2393 (1994).

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR 1.56, pursuant to 37 CFR §1.97(h), the filing of this statement shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR 1.97 (b) insofar as this statement is being filed before the mailing date of a first Office Action.

Also in accordance with 37 CFR §1.97 (g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made, or that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

Respectfully submitted,

Dated: 8 March 1995

By:

April C. Logan

April C. Logan
Registration No. 33,950
THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10666 N. Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(619) 554-2937



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.

April C. Logan
April C. Logan, Reg. No. 33,950

27 April 1995
Date

Applicant	: Sherman)	
)	Group Art Unit:
Serial No.	: 08/355,558)	Unassigned
)	
Filed	: 12/14/94)	Examiner:
)	Unassigned
For	: IN VIVO ACTIVATION OF)	
	TUMOR-SPECIFIC CYTOTOXIC)	
	T CELLS)	Our Ref. TSRI 433.0

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner
of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

In recognition of its continuing duty to disclose pursuant to 37 CFR §1.56, Applicant hereby submits the present Supplemental Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith. Copies of the references cited therein are also enclosed.

The following references became known to Applicant within the past 30 days and are believed relevant for the reasons set forth as follows. Published International Application No. WO 93/24525 (inventors: Melief, et al.) describes human p53 peptides and proteins for use in human T cell response-inducing compositions. Published International Application No. WO 94/02167 (inventor: Levine) describes vaccine compositions comprising a mutant or wild-

Serial No.: 08/355,558



TSRI 433.0

type p53 protein.

Applicant understands that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Supplemental Information Disclosure Statement may be material pursuant to 37 CFR §1.56, pursuant to 37 CFR §1.97(h), the filing of this Statement shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicant is filing the present Statement pursuant to 37 CFR §1.97(b) insofar as this Statement is being filed before the mailing date of a first Office Action.


Also, in accordance with 37 CFR §1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that a search has been made, or that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

Respectfully submitted,


Dated: 27 April 1995

By: April C. Logan
April C. Logan
Registration No. 33,950
THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10666 N. Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(619) 554-2937

C:\WP\1569-IDS.SUP

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					ATTY DOCKET NO. SCR 1569P		SERIAL NO. 08/355,558	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT Sherman				FILING DATE December 14, 1994	
					GROUP Unknown					
U.S. PATENT DOCUMENTS										
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE			
FOREIGN PATENT DOCUMENTS										
EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	FILING DATE			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)										
	1	Di Fiore, et al., <u>Science</u> 237: 178 (1987)								
	2	Dittmer, et al., <u>Nature Gen.</u> 4: 42 (1993)								
	3	Falk, et al., <u>Nature</u> 351: 290 (1991)								
	4	Harlow, et al., <u>Mol. Cell. Biol.</u> 5: 1601 (1985)								
	5	Hinds, et al., <u>Cell Growth Diff.</u> 1: 571 (1990)								
	6	Houbiers, et al., <u>Eur. J. Immunol.</u> 23: 2072-2077 (1993)								
	7	Hunt, et al., <u>Science</u> 255: 1261 (1992)								
	8	Ioannides, et al., <u>Cellular Immunol.</u> 151: 225-234 (1993)								
	9	Ioannides, et al., <u>J. Immunol.</u> 146: 1700 (1991)								
	10	Irwin, et al., <u>J. Exp. Med.</u> 170: 1091 (1989)								
	11	Melief and Kast, <u>Curr. Op. Immunol.</u> 5: 709-713 (1993)								
	12	Vitiello, et al., <u>J. Exp. Med.</u> 173: 1007-1015 (1991)								
EXAMINER					DATE CONSIDERED					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		<div style="text-align: center;"></div>		ATTY DOCKET NO. SCR 1569P		SERIAL NO. 08/355,558	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						APPLICANT Sherman			
						FILING DATE December 14, 1994		GROUP Unknown	
U.S. PATENT DOCUMENTS									
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE		
FOREIGN PATENT DOCUMENTS									
EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	FILING DATE		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)									
	13	Winter, et al., <u>Cancer Res.</u> 52: 4168-74 (1992)							
	14	Yoshino, et al., <u>J. Immunol.</u> 152: 2393 (1994)							
EXAMINER					DATE CONSIDERED				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[illegible]

FOREIGN PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	FILING DATE
	1	WO 93/24525	12/09/93	PCT			5/18/93
	2	WO 94/02167	02/03/94	PCT			7/22/93

[illegible]

DATE CONSIDERED

TN\ACL\SCR1569P.IDS